ProShare Advisors
LSTA icon

ProShare Advisors’s Lisata Therapeutics LSTA Stock Holding History

ProShare Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-76
Closed -$75K – 2334
2014
Q2 		$75K Buy
+76
New +$73.9K ﹤0.01% 2412

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

ProShare Advisors's LSTA Position: Q3 2014 in Review

ProShare Advisors sold out of Lisata Therapeutics (LSTA) in Q3 2014, closing a stake of 76 shares — an estimated $75K sold.

ProShare Advisors first reported a position in LSTA in Q2 2014 and held it in 1 quarter. The position peaked at $75K in Q2 2014. 50 funds tracked by Wall St. Rank hold LSTA as of Q3 2014.

  • ProShare Advisors reported no remaining Lisata Therapeutics position as of Q3 2014 after selling out during the quarter.
  • ProShare Advisors sold 76 Lisata Therapeutics shares in Q3 2014, an estimated $75K.
  • ProShare Advisors first reported a position in Lisata Therapeutics in Q2 2014 and held it in 1 quarter.
  • ProShare Advisors's Lisata Therapeutics position peaked at $75K in Q2 2014.
  • 50 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2014.

Based on ProShare Advisors's 13F filing for Q3 2014, filed 6 Nov 2014.